The Value Discussion in Cancer Care Escalates: NICE and Roche

According to Sir Andrew Dillon, chief executive of NICE, the high price that Roche is demanding for Kadcyla is beyond the means of NHS to cover.

Sir Andrew Dillon, Nice chief executive says that the NHS cannot afford to pay Roche the high price it is demanding for its "miracle" breast cancer treatment. The drugs giant has responded by insisting that Nice is the only health body to conclude that Kadcyla is not good value for money.

Listen to the argument from both sides:

Source: The Telegraph